Jun 20 |
Gilead Sciences' Twice-Yearly Shot Prevents 100% of HIV Cases in Trial, Shares Jump
|
Jun 20 |
Gilead's Twice-Yearly Shot Prevents HIV
|
Jun 20 |
Gilead Shot Prevents All HIV Cases in Trial of African Women
|
Jun 20 |
Gilead gains on trial win for twice-yearly HIV PrEP therapy
|
Jun 20 |
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
|
Jun 20 |
Twice-yearly shots of Gilead HIV drug effective in large prevention study
|
Jun 20 |
Why Wall Street Is Chasing Ozempic Wannabes
|
Jun 19 |
Gilead and Kite Pharma Celebrates Pride Month
|
Jun 19 |
Shareholders in Gilead Sciences (NASDAQ:GILD) are in the red if they invested a year ago
|
Jun 17 |
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
|